Novel Use of Vitamin B2 as a Fluorescent Tracer in Aerosol and Droplet Contamination Models in Otolaryngology

Edward S. Sim, BS1, Harish Dharmarajan, MD2, Devi Sai Sri Kavya Boorgu, BS1, Lindsey Goyal, MD2, Michael Weinstock, MD2, Rachel Whelan, MD2, Monika E. Freiser, MD, MPH2, Timothy E. Corcoran, PhD3, Noel Jabbour, MD2, Eric Wang, MD2, and David H. Chi, MD2

Abstract

Objective: During the COVID-19 era, a reliable method for tracing aerosols and droplets generated during otolaryngology procedures is needed to accurately assess contamination risk and to develop mitigation measures. Prior studies have not investigated the reliability of different fluorescent tracers for the purpose of studying aerosols and small droplets. Objectives include (1) comparing vitamin B2, fluorescein, and a commercial fluorescent green dye in terms of particle dispersion pattern, suspension into aerosols and small droplets, and fluorescence in aerosolized form and (2) determining the utility of vitamin B2 as a fluorescent tracer coating the aerodigestive tract mucosa in otolaryngology contamination models.

Methods: Vitamin B2, fluorescein, and a commercial fluorescent dye were aerosolized using a nebulizer and passed through the nasal cavity from the trachea in a retrograde-intubated cadaveric head. In another scenario, vitamin B2 was irrigated to coat the nasal cavity and nasopharyngeal mucosa of a cadaveric head for assessment of aerosol and droplet generation from endonasal drilling. A cascade impactor was used to collect aerosols and small droplets ≤14.1 µm based on average aerodynamic diameter, and the collection chambers were visualized under UV light.

Results: When vitamin B2 was nebulized, aerosols ≤5.4 µm were generated and the collected particles were fluorescent. When fluorescein and the commercial water tracer dye were nebulized, aerosols ≤8.61 µm and ≤2.08 µm respectively were generated, but the collected aerosols did not appear visibly fluorescent. Endonasal drilling in the nasopharynx coated with vitamin B2 irrigation yielded aerosols ≤3.30 µm that were fluorescent under UV light.

Conclusion: Vitamin B2’s reliability as a fluorescent tracer when suspended in aerosols and small droplets ≤14.1 µm and known mucosal safety profile make it an ideal compound compared to fluorescein and commercial water-based fluorescent dyes for use as a safe fluorescent tracer in healthcare contamination models especially with human subjects.

Keywords
otolaryngology, COVID-19, aerosol, aerodynamics, contamination, impactor

Introduction

Due to the global COVID-19 pandemic, there has been an increased interest in studying the aerodynamic properties of aerosols and droplets. There is uncertainty whether aerosols may harbor enough viable SARS-CoV-2 virus to cause infection; a comprehensive understanding of aerosol and droplet behavior and mitigation strategies are needed in order to effectively limit infectious spread. Otolaryngologists, in particular, are at high-risk of nosocomial SARS-CoV-2 infections due to the numerous aerosol and droplet generating procedures involving manipulation of potentially high viral load tissue. Distinctly characterizing aerosols and droplets based on aerodynamic diameter is critical to assessing risk of contamination due to the varying routes of transmission and
infectious potential of viruses suspended in different sized particles. In this study, aerosols are defined with an aerodynamic diameter $\leq 10\mu m$ whereas droplets are characterized as those with diameters $>10\mu m$. This is in accordance with differences in particle dispersion and deposition into upper and lower airways.\(^2\) Multiple fluorescent tracers such as Glo Germ (Glo Germ Company, Moab, Utah) and fluorescein have been used in healthcare contamination models.\(^3,4\) For risk assessment of otolaryngology procedures, fluorescein has been the primary tracer utilized.\(^5,7\) However, these tracers are limited due to their potential toxicity in humans and unknown capacity to fluoresce in an aerosolized form. Riboflavin, vitamin B2, is a water-soluble vitamin that exhibits fluorescence under UV light due to the $\pi$ conjugation and resonance present in its chemical structure.\(^8\) Riboflavin’s fluorescent properties have allowed for its use as a tracer in many different applications. In this study, we evaluate the utility of riboflavin, vitamin B2, as a fluorescent aerosol tracer, compare its properties to conventional fluorescent tracers, and explore its potential applications in human studies.

**Materials and Methods**

This study was conducted with approval from the University of Pittsburgh Committee for Oversight of Research and Clinical Training Involving Decedents (CORID #1054). Vitamin B2 1 g/L in 0.9% normal saline, fluorescein 1 g/L in 0.9% normal saline, and a stock solution of a commercially available green fluorescent water tracing dye (Factor Direct Chemicals, Copiague, New York) were used as reagents. Aerosols of these solutions were generated using an AeroEclipse II Breath Actuated Nebulizer (BAN) (Trudell Medical International, London, ON). The BAN system was used to create aerosol particles with an average mass median aerodynamic diameter (MMAD) of 2.8 $\mu m$.\(^9,10\) The trachea of an adult cadaver head was intubated retrograde with an 8.0 ETT. Vitamin B2 irrigation was used to create aerosol particles with an average mass median aerodynamic diameter (MMAD) of 2.8 $\mu m$. The trachea of an adult cadaver head was intubated retrograde with an 8.0 ETT with the distal tip projecting into the nasopharynx and confirmed with an endoscope. The BAN nebulizer was attached to the proximal end of the ETT and generated aerosols that traveled through the ETT and exited through the nares (Figure 1B). Aerosol plumes could be visualized under
room light and were accentuated under UV blacklight when fluorescent solutions were used (Supplemental Video).

A Model 170 Next Generation Impactor™ (NGI™) was used to collect particles into 8 stages with the following aerodynamic diameters (D50, cutoff diameter at 50% collection efficiency): 14.1 µm, 8.61 µm, 5.39 µm, 3.30 µm, 2.08 µm, 1.36 µm, 0.98 µm, and less than 0.98 µm.11,12 Each impactor stage reflects an average particle aerodynamic diameter given an input flow rate of 15 L/min (Figure 1A). This size range characterizes aerosols that are likely to reach the infraglottic airway (<10 µm) and settle into lung alveoli (<5 µm).2 Each stage has a corresponding capture chamber that was lined with a removable piece of aluminum foil. The collected particulate matter on each foil was visualized under UV light following each trial. The nares of the cadaveric head were placed directly adjacent to the NGI™ input nozzle (Figure 1C). Each trial lasted 2 minutes and included using the following solutions via the BAN system to generate aerosols: 0.9% normal saline, 1 g/L riboflavin (vitamin B2), 1 g/L fluorescein and a stock solution of a green fluorescent water tracer (Factor Direct Chemicals, Copiague, New York). We also performed a trial of endonasal drilling in a cadaveric head with a coarse diamond burr (Stryker©, Kalamazoo, MI) using 1 g/L vitamin B2 solution for irrigation; in this scenario, vitamin B2 irrigation was used to coat the nasal cavity and nasopharyngeal mucosa prior to drilling and intermittently while drilling occurred (Figure 1D). A UV flashlight was used to visualize the filtrate at each stage in a dark room. The impactor was used to determine the aerodynamic size distribution of the aerosol and small droplet particles generated from each simulation scenario.

**Results**

The vitamin B2, fluorescein, and commercial green tracer dye exhibited baseline fluorescence in solution form. As a negative control, the BAN system was loaded with 0.9% normal saline to ensure that the saline solution did not exhibit fluorescence and that the BAN system could effectively produce aerosols detectable by the impactor. For this trial, aerosols approximately 3.30 µm or smaller were generated, but the small droplets did not appear fluorescent under UV light (Figure 2A; Table 1). The 1 g/L fluorescein solution generated aerosols ≤8.61 µm. The collected particles that were between 3.30 µm and 8.61 µm in diameter were brightly fluorescent under UV light, but this diminished quickly in the matter of minutes. A red-orange colored
Risk with otolaryngology procedures is important.\textsuperscript{16} Negative pressure air ventilation of the nasal cavity or nasopharynx. COVID-19 may have high viral loads in the upper aerodigestive tract mucosa. Its fluorescent property allows visible fluorescence in aerosol suspension. All three tracers exhibited fluorescence in solution form and thus could be used similarly in large droplet contamination trials.\textsuperscript{14.1} 8.61 5.39 3.30 2.08 1.36 0.98 <0.98

| Tracer                        | 14.1 | 8.61 | 5.39 | 3.30 | 2.08 | 1.36 | 0.98 | <0.98 |
|------------------------------|------|------|------|------|------|------|------|-------|
| Saline\textsuperscript{b}    | -    | -    | -    | +    | +    | +    | +    | +     |
| Fluorescein\textsuperscript{b}| -    | +    | +    | +    | +    | +    | +    | +     |
| Green water dye\textsuperscript{b} | -    | -    | -    | -    | -    | +    | +    | +     |
| Vitamin B2 (nebulized)       | -    | -    | +    | +    | +    | +    | +    | +     |
| Vitamin B2 (irrigation)      | -    | -    | -    | +    | +    | +    | +    | +     |

Note. *no visibly apparent fluorescence under UV light. + Denotes presence of particle aggregates. °No particles present at the specific impactor stage.

Filtrate remained in the stages and did not appear visibly fluorescent (Figure 2B). When the commercial green tracer dye was nebulized with the BAN system, the impactor yielded red-orange colored particles ≤3.30 µm that did not appear fluorescent under UV light (Figure 2C). With the nebulized vitamin B2 solution, aerosols ≤5.39 µm in diameter were generated, and the filtered particles were visibly fluorescent under UV light (Figure 2D). For the endonasal drilling trial, small particles ≤3.30 µm exhibiting fluorescence were generated (Figure 2E).

Discussion

An effective method for tracing aerosols is integral to understanding baseline risk and designing mitigation strategies for reducing the transmission risk of SARS-CoV-2. Aerosols that are ≤10 µm are of great importance due to their ability to remain airborne and travel long distances.\textsuperscript{2} Particles that are 5 µm or less in diameter can penetrate the lower airways, potentially contributing to an increased severity and likelihood of infection.\textsuperscript{13-15} In this study, we have compared the fluorescent properties of different tracers in aerosolized form. Of the different fluorescent solutions analyzed, Vitamin B2 was the superior tracer based on fluorescence reliability across a range of aerosol sizes under 14.1 µm. Fluorescein and commercial green tracer solutions did not exhibit reliable visible fluorescence in aerosol suspension. All three tracers exhibited fluorescence in solution form and thus could be used similarly in large droplet contamination trials.

Vitamin B2 can be used as a coating agent for upper aerodigestive tract mucosa. Its fluorescent property allows for survey of aerosols and droplets generated from instrumentation of the nasal cavity or nasopharynx. COVID-19 positive patients may have high viral loads in the upper aerodigestive tract, so stratifying the aerosol and droplet risk with otolaryngology procedures is important.\textsuperscript{16} Vitamin B2 has significant advantages compared to other tracers in that it is inexpensive, readily available and has an established safety profile. Physiologically, riboflavin functions as an essential coenzyme in multiple redox reactions required for cellular respiration. Besides its essential biochemical functions, riboflavin has therapeutic applications when administered either orally for migraine prophylaxis and cataract risk reduction or topically for treating surgery-refractory keratoconus.\textsuperscript{17-20} Vitamin B2 has been utilized safely as a tracer to assess medication compliance in children. In clinical trials, the study drug can be tracked by the fluorescence of vitamin B2 excreted in the urine. It has also been used in contact contamination trials.\textsuperscript{21-23} There is no defined FDA upper limit of oral daily intake due to a lack of evidence of any observable adverse effects from excess riboflavin ingestion even when consuming 400 mg per day for 3 months.\textsuperscript{24,25} This may be due to its limited capacity for absorption by the gastrointestinal mucosa and its rapid urinary clearance.\textsuperscript{26}

In contrast to the well-documented safety of vitamin B2, there have been multiple reports of harmful reactions to conventional tracers such as fluorescein when administered topically, intravenously, and orally. Fluorescein is a widely used fluorescent marker in ophthalmology, often administered intravenously or orally for diagnostic angiography of iris vasculature. Despite the prevalence of fluorescein use, studies have reported 5-10% of patients experiencing adverse events from intravenous fluorescein injection that include mild transient reactions such as vomiting and nausea and more severe reactions such as anaphylaxis, cardiac arrest, shock, basilar artery ischemia, and myocardial infarction.\textsuperscript{27,28} Topical application of fluorescein on the corneal surface is considered generally safe when used to detect corneal injury, but there have been cases of severe allergic reactions reported.\textsuperscript{29,30} Some have suggested requiring intradermal skin testing to determine hypersensitivity to fluorescein prior to use if an allergy is suspected, but skin testing has failed to reliably identify reactors in prospective studies.\textsuperscript{31} While severe adverse reactions to fluorescein may be rare, there is a lack of literature outlining the upper tolerable levels of fluorescein. This prohibits its safe use as a tracer in human trials to study aerosol and droplet dispersion. Most commercially available fluorescent dyes are not approved for use in humans; many have warnings regarding contact with the skin or mucosal surfaces.\textsuperscript{32}
Supplemental Material

Supplemental material for this article is available online.

References

1. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382(16):1564-1567.
2. Tellier R, Li Y, Cowling BJ, Tang JW. Recognition of aerosol transmission of infectious agents: a commentary. BMC Infect Dis. 2019;19(1). doi:10.1186/s12879-019-3707-y
3. Chahal AM, van Dewark K, Gooch R, Fukushima E, Hudson ZM. A rapidly deployable negative pressure enclosure for aerosol-generating medical procedures. MedRxiv. doi:10.1101/2020.04.14.20063958
4. Feldman O, Meir M, Shavit D, Idelman R, Shavit I. Exposure to a surrogate measure of contamination from simulated patients by emergency department personnel wearing personal protective equipment. JAMA. 2020;323(20):2091-2093.
5. Chen JX, Workman AD, Chari DA, et al. Demonstration and mitigation of aerosol and particle dispersion during mastoidectomy relevant to the COVID-19 era [published online May 8, 2020]. Otol Neurotol. doi:10.1097/MAO.0000000000002765.
6. Workman AD, Welling DB, Carter BS, et al. Endonasal instrumentation and aerosolization risk in the era of COVID-19: simulation, literature review, and proposed mitigation strategies. Int Forum Allergy Rhinol. 2020;10(7). doi:10.1002/alr.22577
7. Sharma D, Rubel KE, Ye MJ, et al. Cadaveric simulation of endoscopic endonasal procedures: analysis of droplet splatter patterns during the COVID-19 pandemic. Otolaryngol Head Neck Surg. 2020;163(1):145-150.
8. Drami¢anin M. Biomedical applications of luminescence thermometry. In: Drami¢anin M (ed.) Luminescence Thermometry: Methods, Material, and Applications. Elsevier Science; 2018.
9. Landon C, Garza G. Nebulizer aerosol performance and patient acceptance in cystic fibrosis. Am J Respir Crit Care Med. 2016;193.
10. AeroEclipse® II. Breath Actuated Nebulizer. https://www. oxycare.eu/out/mediAeroEclipse_II_Visual_Aid.pdf. Accessed June 14, 2020.
11. NextGenerationImpactor(NGI).CopleyScientific,https://www. copleyscientific.com/browse/inhaler-testing/aerodynamic- particle-size-distribution-apsd-apsd-for-metered-dose-inhalers-mdis/spacers-vhcs-metered-dose-inhalers-mdis-aerodynamic- particle-size-distribution-apsd/next-generation-impactor-ngi- spacers-vhcs/. Accessed June 14, 2020.
12. Marple VA, Roberts DL, Romay FJ, et al. Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part I: design. J Aerosol Med. 2003;16(3):283-299.
13. Memoli MJ, Czajkowski L, Reed S, et al. Validation of the wild-type influenza A human challenge model H1N1pdmMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. Clin Infect Dis. 2015;60(5):693-702.
14. Joynt GM, Wu WK. Understanding COVID-19: what does viral RNA load really mean? Lancet Infect Dis. 2020;20(6):635-636.
15. Bustin SA, Mueller R. Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin Sci (Lond). 2005;109(4):365-379.
16. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177-1179.
17. Thompson DF, Saluja HS. Prophylaxis of migraine headaches with riboflavin: a systematic review. J Clin Pharm Ther. 2017;42(4):394-403.
18. Glaser TS, Doss LE, Shih G, et al. The Association of Dietary Lutein plus Zeaxanthin and B Vitamins with cataracts in the age-related eye disease study: AREDS Report No. 37. Ophthalmology. 2015;122(7):1471-1479.
19. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003;135(5):620-627.
20. Goldich Y, Marcovich AL, Barkana Y, Avni I, Zadok D. Safety of corneal collagen cross-linking with UV-A and riboflavin in progressive keratoconus. Cornea. 2010;29(4):409-411.
21. Cluss PA, Epstein LH. A riboflavin tracer method for assessment of medication compliance in children. Behav Res Methods Instrum Comput. 1984;16(5):444-446.
22. Ramanujam VM-S, Anderson K, Grady J, Lu L-J. Monitoring compliance using riboflavin (vitamin B2) as a tracer for a clinical trial. Cancer Res. 2007;67(9 suppl).
23. Ivanic WA, Nishioka MG, Barnes RH Jr, Hubal EC, Morara M, Bortnick SM. Development and evaluation of a quantitative video-fluorescence imaging system and fluorescent tracer for measuring transfer of pesticide residues from surfaces to hands with repeated contacts. Ann Occup Hyg. 2004;48(6):519-532.
24. Riboflavin. Health Professional Fact Sheet, https://ods.od.nih.gov/factsheets/Riboflavin-HealthProfessional/. Accessed July 10, 2020.
25. Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia. 1994;14(5):328-329.
26. Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academies Press; 1998.
27. Marcus DF, Bovino JA, Williams D. Adverse reactions during intravenous fluorescein angiography. Arch Ophthalmol. 1984;102(6):825.
28. Gómez-Ulla F, Gutiérrez C, Seoane I. Severe anaphylactic reaction to orally administered fluorescein. Am J Ophthalmol. 1991;112(1):94.
29. el Harrar N, Idali B, Moutaouakkil S, et al. Choc anaphylactique par application de fluorescéine sur la conjonctive oculaire [Anaphylactic shock caused by application of fluorescein on the ocular conjunctiva]. Presse Med. 1996;25(32):1546-1547.
30. Shahid H, Salmon JF. Anaphylactic response to topical fluorescein 2% eye drops: a case report. J Med Case Rep. 2010;4:27.
31. Kalogeromitros DC, Makris MP, Rouvas A, Theodossiadis PG, Spanoudaki N, Papaioannou D. Skin testing and adverse reactions in fluorescein: a prospective study. Allergy Asthma Proc. 2007;28(4):472-476.
32. Fluorescent Water Tracing Dye - Red or Green. Factory Direct Chemicals, https://www.factorydirectchemicals.com/products/fluorescent-water-tracing-dye. Accessed July 12, 2020.
33. Kohanski MA, Palmer JN, Cohen NA. Aerosol or droplet: critical definitions in the COVID-19 era [published online April 23, 2020]. Int Forum Allergy Rhinol. 2020;10.1002/alr.22591.
34. American Academy of Otolaryngology–Head and Neck Surgery. Academy supports CMS, offers specific nasal policy. https://www.entnet.org/content/academy-supports-cms-offers-specific-nasal-policy. Accessed April 25, 2020.